The widespread human exposure to bisphenol A (BPA), a xenoestrogen interfering with developmental processes, raises the question of the mechanisms determining fetal exposure to BPA. A physiological model was developed in ewes to determine whether the pregnancy-associated physiological changes and the metabolic specificities of the fetal-placental unit can influence BPA toxicokinetics (TK) and fetal exposure to BPA. In a first longitudinal study, BPA was infused (2 mg/[kgÁday] i.v. for 1 day) into ewes before breeding, at early and late stages of gestation, and after lambing. In a second study, BPA and BPA-glucuronide (BPA-G) were infused intravenously into pregnant ewes or into fetuses at 4 mo of gestation. BPA and its metabolites were assayed in maternal and fetal plasma and amniotic fluid sampled at steady state and after the end of the infusion. The pregnancy status did not modify the TK parameters of BPA and of BPA-G. Five percent of the BPA dose infused into the pregnant ewe was transferred across the placenta to the fetus. The fetal-placental unit was very efficient in metabolizing BPA into conjugated compounds; those metabolites remained trapped in the fetalplacental compartment, leading to a high fetal exposure to BPA conjugates. Taking into account a body weight adjustment, the ovine fetus in late pregnancy is exposed to a BPA dose similar to that of its mother. In contrast to its mother, the fetus exhibits much higher and sustained exposure to BPA metabolites without evidence of their hydrolysis.
INTRODUCTION
Bisphenol A (BPA) is a xenoestrogen widely used as a monomer in the manufacture of epoxy resins and polycarbonate plastics, which could contribute to the almost ubiquitous human exposure to BPA [1] . In humans, BPA is converted extensively in the liver to BPA-glucuronide (BPA-G) and to a lesser extent to BPA-sulfate (BPA-S), which are inactive metabolites in terms of estrogenicity [2] . Biomonitoring data have shown large individual variations in human plasma BPA concentrations, with values up to 66.50 ng/ml (291.28 nM) [1] . This large range in BPA plasma concentrations could reflect the physiological variability of BPA toxicokinetics (TK). For instance, the high levels of BPA detected in pregnant women compared with nonpregnant women [1] raise the possibility that the BPA TK might be different in pregnant versus nonpregnant women, which could contribute to higher fetal exposure to BPA.
Furthermore, high BPA levels have been reported in the fetal-placental compartment, in the blood of the umbilical cord, in the placenta, and in the amniotic fluid [1] , suggesting a transfer of BPA from mother to fetus. In addition, the internal exposure of the fetus to BPA could be exacerbated by the reactivation of conjugates (BPA-G and BPA-S) to BPA by the fetal-placental tissue and the limited drug-metabolizing systems of the fetus [3] [4] [5] .
The predominant concern in the risk assessment of BPA arises from several studies that found a variety of adverse effects in rodents exposed to low doses of BPA during gestation [6, 7] . However, to translate the findings from animal studies to estimate the health risk of environmental exposures to humans, it is essential to document the factors determining fetal internal exposure to BPA, including 1) the maternal internal BPA exposure, 2) the BPA placental transfer, 3) the binding of BPA to maternal and fetal plasma proteins, 4) the metabolism of BPA by the fetal-placental unit, and 5) the possible recirculation of BPA between the amniotic fluid and the fetal circulation. To evaluate these physiological factors simultaneously, we developed a pregnant sheep model that enables fetal vascular and amniotic sac cannulation and allows direct administration and monitoring of BPA and metabolite levels over time in both fetal and maternal blood, which is not possible in rodents. Sheep have long been used as an animal model for studying the interaction of the maternal-placental-fetal unit [8, 9] and for characterizing the disposition of drugs in the maternal-placental-fetal unit [10, 11] . Furthermore, despite the fact that the syndesmochorial placental structure does not match the hemochorial, multivillous nature of the human placenta, important similarities in functional structure exist between human and ovine placentae, notably the contact of the trophoblastic layer with desquamated areas of the maternal epithelium in sheep [9] .
The present study was intended to determine whether the pregnancy-associated physiological changes and the metabolic specificities of the fetal-placental unit could influence BPA TK, leading to higher exposure of the fetus to BPA. The goals of our approach were to evaluate 1) the impact of pregnancy on BPA and BPA-G maternal TK, 2) the TK parameters of BPA and BPA-G in fetal compartments, and 3) the BPA and BPA-G placental transfers. The binding of BPA to plasma proteins was also determined in ewes and in fetuses.
MATERIALS AND METHODS

Animals and Surgery
All animal procedures were carried out in accordance with accepted standards of humane animal care under agreement 31-1155545 from the French Ministry of Agriculture. Ewes were housed indoors in collective pens. Forty hours before the bleeding periods as well as after surgery and until lambing, the ewes were placed in individual pens. Contention stress was minimized by juxtaposing the pens so that the ewes could still see and smell each other. All animals received two daily meals of a 18% protein concentrate, and hay and water were given ad libitum.
Eleven 6-mo-old Lacaune ewes (body weight, 45.67 6 4.49 kg [mean 6 SD]) were synchronized for estrus by insertion of an intravaginal sponge containing 20 mg of flurogestone acetate (Chronogest CR; Intervet) for 14 days. At the time of sponge removal, the ewes were given an intramuscular administration of 280 IU of equine chorionic gonadotropin (Chronogest PMSG; Intervet) and then inseminated 48 h after the sponge removal. A Lacaune ram with a marking harness was introduced into the flock 14 days later to mate with the nonpregnant females, and the mating patterns were monitored. Pregnancy was diagnosed by the Pregnancy-Associated Glycoproteins test according radioimmunoassay validated method [12] 26 days after artificial insemination and confirmed by ultrasonography.
One fetus per ewe (eight females and three males) was chronically catheterized between 108 and 117 days of gestation with catheters placed in one carotid artery, in one jugular vein, and in the amniotic cavity. Following general anesthesia with thiopental sodium (15 mg/kg i.v.) and isoflurane (1% to 1.5%) and surgical preparation, the uterus was accessed through a sidelong incision on the left flank of the ewe. The fetal head was identified by intraabdominal palpation and externalized. The uterine wall was incised as well as fetal membranes that were fixed together by Collins forceps with special care to control any loss of fetal fluids. The fetal carotid artery was catheterized with a polyvinyl catheter (inner diameter, 0.81 mm; outer diameter, 1.69 mm; Medical Tubing). Similarly, a Tygon S-54-HL catheter (inner diameter, 1.02 mm; outer diameter, 1.78 mm; Saint-Gobain) was placed in the jugular vein as well as in the amniotic cavity. The catheters were then secured to the fetal skin, and 500 mg of ampicillin were injected in the amniotic cavity. The uterus was closed with continuous sutures including all fetal membranes and the uterine wall. The abdominal incision was closed using a two-layer suture standard procedure. Before the skin was sutured, all catheters were tunneled subcutaneously and exteriorized through a small flank incision in the sublumbar fossa. The catheters were filled with a heparin-saline solution (1000 IU/ml) and sealed. The exteriorized part of the catheter was wrapped in a compress soaked in povidone-iodine and was stored in a pouch attached to the ewe's abdominal flank. Ewes received tolfenamic acid (2 mg/kg i.v.) and long-acting amoxicillin (20 mg/kg i.m. twice, two days apart). After surgery, the animals were housed in individual, adjacent pens and had free access to food and water. Ewes were allowed to recover for 4-8 days before experimentation. The catheters were flushed with 2 ml of sterile heparin-saline solution (1000 IU heparin/ml) once daily until the end of the experiment (last infusion) and twice a week until parturition. Blood and amniotic fluid samples were taken from fetuses using strict aseptic procedures.
Ewes delivered spontaneously at 143.1 6 2.1 days of gestation, corresponding to normal gestation length in sheep.
Solution Preparation and Animal Treatments
The BPA (purity, !99%) and all chemicals were purchased from SigmaAldrich. The BPA was extemporaneously dissolved in ethanol/propylene glycol (1/49 vol/vol) at concentrations ranging from 3.02 to 45.12 mM (0.69-10.30 mg/ml). The BPA-G was purified in our laboratory as previously described [13] and was extemporaneously dissolved in 0.9% NaCl buffer at concentrations ranging from 1.83 to 80.90 mM (0.74-18.47 mg/ml).
For maternal infusions, the concentrations of BPA and BPA-G solutions infused into each animal were adjusted to the body weight recorded within the two previous days. For fetal infusions, the body weight of fetuses at 120 days of gestation was arbitrarily chosen to be 2.5 kg [14] . Each compound was infused intravenously for 24 h into the jugular vein via an indwelling catheter connected to a portable syringe pump as previously described [15] .
Experimental Design Experiment 1. Effect of pregnancy on maternal exposure. Experiment 1 was designed to evaluate the impact of pregnancy on the maternal TK parameters of BPA and BPA-G. This longitudinal study was performed on ewes challenged with BPA infusions at four different periods: 1 mo before breeding (period 1, first control period, n ¼ 6), 1 mo of pregnancy (period 2, corresponding to early pregnancy, n ¼ 6), 4 mo of pregnancy (period 3, corresponding to late pregnancy, n ¼ 8), and 1 mo after lambing (period 4, second control period, n ¼ 4). During periods 1 and 2, ewes received infusions of BPA (2 mg/[kgÁday] i.v. for 1 day). For periods 3 and 4, each ewe received both BPA and BPA-G intravenous infusions for 1 day at two different sessions 7 days apart according to a crossover design (BPA and BPA-G doses at the same molar dose: 2 and 3.54 mg/[kgÁday], respectively). This dose was selected on the basis of a preliminary TK study in sheep [15] 
Sample Collection and Processing
All materials used for the preparation of solutions, sampling, processing, and analysis were in either glass or BPA-free plastic containers.
Maternal and fetal serial blood and amniotic fluid samples were collected before the infusion and during the last 3 h of the infusion to determine steadystate concentrations (Css). After the end of the infusion, the maternal blood samples were collected at 4, 8, 15, 30, 45, 60, 90, and 120 min and at 4, 6, 8, 10, 22, 34, and 46 h. Fetal blood samples were collected at 15, 30, 60, and 120 min and at 4, 6, 8, 10, 22, 34, and 46 h, and amniotic fluid samples were collected at 22 and 46 h. For ewes, 2-ml blood samples were collected by direct puncture of the right jugular vein. For fetuses, 1-ml arterial blood and amniotic fluid samples were withdrawn through the catheters. Samples were collected in polypropylene tubes with (blood) or without (amniotic fluid) heparin. All samples were immediately chilled in ice and centrifuged for 10 min at 3000 3 g and 48C, after which the plasma was decanted. All samples were stored at À208C until assayed.
BPA and Metabolite Assays
The BPA, BPA-G, and BPA-S in plasma and amniotic fluid samples were assayed simultaneously as previously described [13] .
The calibration curves ranged from 4.4 to 2190 nM (1-500 ng/ml), 124 to 24 752 nM (50-10 000 ng/ml), and 6.8 to 1364 nM (2.1-420 ng/ml) for BPA, BPA-G, and BPA-S, respectively. The mean intra-and interday coefficients of variation for three concentration levels and for BPA, BPA-G, and BPA-S were lower than 15%, and the limits of quantification (LOQs) were validated at 4.4 nM (1 ng/ml), 124 nM (50 ng/ml), and 6.8 nM (2.1 ng/ml), respectively.
BPA-Protein Binding
The percentage of free BPA (i.e., BPA unbound to plasma proteins) in maternal and fetal plasma was determined from three plasma samples obtained at steady state for each ewe and each period and from the plasma of three fetuses collected at steady state.
In vitro protein binding of BPA was evaluated by equilibrium dialysis with a cellulose membrane with a molecular weight cutoff of 5 kDa using [
TK Analysis
All TK analyses were performed using WinNonlin software (Version 5.3; Pharsight Corporation). Individual plasma concentration-time profiles of BPA and BPA-G were analyzed according to a noncompartmental approach. For the second session of the crossover, when fetuses showed residual detectable levels of BPA-G from the first session, BPA-G concentrations were corrected by the mean of those residual concentrations determined just before the administration. For BPA-G infusions, the sparse data option of WinNonlin was used, allowing computation of the different standard errors associated with the calculated parameters. The area under the plasma concentration-time curve from t ¼ 0 to infinity (AUC 0-inf ) was obtained by dividing the last observed quantifiable plasma concentration by the slope of the terminal phase as estimated by linear regression by using the best fit option of WinNonlin.
The BPA (or BPA-G) clearance (Cl) was obtained using the following equation:
The mean residence time (MRT), the steady-state volume of distribution (Vss) and the terminal half-life (t 1/2 ) were computed in accordance with classical TK equations [18] described in the Supplemental Data (available online at www. biolreprod.org).
The fraction of BPA metabolized in BPA-G (F BPA-BPA-G ) in ewes was calculated as the ratio between the AUC 0-24h of BPA-G obtained after an intravenous administration of BPA (AUC BPA!BPA-G ) and corresponding value obtained after an intravenous administration of BPA-G at the equivalent molar dose of 8.8 lmol/kg/day for the two substances using the following equation:
The BPA maternal-fetal transfer was estimated for each fetus as the input rate of BPA from dam to fetus during maternal exposure with the following equation:
where Css BPA is the mean fetal BPA plasma concentration reached at steady state during the BPA infusion to its mother and BPA Clearance Fetus is the mean fetal BPA clearance determined in the first part of experiment 2 (i.e., after fetal BPA administration). This input rate was then expressed as the percentage of the total maternal dose (lmol) transferred to fetal compartment.
The placental and nonplacental clearance parameters of BPA in the ewe and fetus were calculated with the mean BPA fetal and maternal Css obtained after the maternal and fetal administrations using the two-compartment open TK model of the maternal-fetal unit described by Szeto [19] . This model assumes steady-state plasma concentrations and BPA elimination from both the maternal and fetal compartments. Placental and nonplacental clearances were expressed as percentages of total BPA plasma clearance. For additional information on the TK model, see the Supplemental Data.
Statistical Analysis
Statistical analyses were performed using Systat 12.0 (SPSS, Inc.). The effect of the physiological status on the maternal BPA and BPA-G plasma Css, on the BPA free fraction, and on the BPA and BPA-G TK maternal parameters was assessed using ANOVA with period as a fixed-effect factor followed by pairwise post hoc comparison. To evaluate the time course of the decline of BPA-G and BPA-S concentrations in fetal plasma after maternal BPA administration or after BPA and BPA-G fetal administrations, the ratio between BPA-G or BPA-S concentrations and the corresponding mean steadystate levels at each sampling time after the arrest of infusion were analyzed using a one-way ANOVA with sampling time as a fixed factor followed by Dunnett post hoc comparisons.
After maternal and fetal BPA administration, mean BPA-G fetal blood concentrations were compared to mean amniotic fluid concentrations using a paired t-test. Ratios between the concentrations of metabolites and the concentrations of BPA in fetal plasma at steady state were compared with the corresponding ratios in maternal plasma using a paired t-test. Figure 1 shows the time courses of the mean plasma concentrations (nM) of BPA, BPA-G, and BPA-S during and after a 24-h intravenous infusion of BPA at the dose of 2 mg/ (kgÁday) for the four periods. The BPA TK parameters determined for each period are summarized in Table 1 . For each period, BPA concentrations decreased rapidly below the LOQ of the assay in less than 2 h after the end of the infusion. By contrast, high plasma levels of BPA-G were observed during and after BPA infusion. For a BPA external exposure of 2 mg/(kgÁday), the overall mean plasma Css were 198 6 42 nM (45.22 6 9.63 ng/ml), 1918 6 407 nM (775 6 164 ng/ ml), and 21.43 6 9.67 nM (6.60 6 2.98 ng/ml) for BPA, BPA-G, and BPA-S, respectively. The mean plasma BPA Css obtained at the early stage of pregnancy were slightly higher than those obtained at the first control nonpregnant stage (P , 0.05) but did not differ from those obtained during the second control nonpregnant stage ( Table 1 ), suggesting that this difference cannot be attributed to the pregnancy status. The overall mean steady-state ratios of BPA-G to BPA and of BPA-S to BPA were 10.05 6 2.98 and 0.12 6 0.06, respectively. The overall mean free plasma BPA (unconjugated BPA not bound to plasma protein) fraction was 6.21% 6 0.70% and was not modified by the physiological status. Consequently, for the mean total BPA concentration of 45.2 ng/ml (198 nM), the internal exposure of ewes to free bioactive BPA was 2.81 ng/ml (12.3 nM).
RESULTS
Experiment 1. Effect of Pregnancy on Maternal Exposure
The mean BPA plasma clearances ranged between 42.9 and 55.9 ml/(kgÁmin) for the four periods and were not affected by the physiological status (P . 0.05). The BPA MRT at the late stage of pregnancy was slightly higher than that obtained at the first nonpregnant stage (P , 0.05), but this difference cannot be attributed to the pregnancy status. In ewes at a late pregnancy stage, BPA was extensively conjugated into BPA-G after BPA intravenous administration, with a biotransformation rate of 96% 6 22%.
The BPA-G TK parameters were evaluated in late pregnancy and after lambing, after a 24-h intravenous infusion of BPA-G at a dose of 3.54 mg/(kgÁday) ( Table 2 ). The mean plasma BPA-G clearances were 5.89 and 5.08 ml/(kgÁmin) in late pregnancy and after lambing, respectively. The pregnancy status did not modify the maternal internal exposure to BPA-G.
Experiment 2. Maternal-Fetal Exposure and Fetal TK Parameters
Maternal-fetal exposure after fetal infusion. Figure 2 depicts the time courses of concentrations of BPA and its metabolites in maternal and fetal plasmas for a representative pregnant ewe during and after fetal 24-h intravenous infusions of BPA and BPA-G.
During the fetal BPA infusion at a dose of 5 mg/(kgÁday), the mean fetal BPA Css was 109.1 6 19.8 nM (24.92 6 4.53 ng/ml) ( Table 3 ) and decreased rapidly after the end of the infusion, with a t 1/2 of 0.89 6 0.83 h. By contrast, the fetal plasma BPA-G and BPA-S levels were very high (8653 6 2492 and 369 6 124 nM, respectively) until 10 h after the end of the BPA infusion, then decreased slowly and were significant lower than steady-state values 118 h afterward (P , 0.05). The BPA plasma clearance by the fetal-placental unit was 250 6 78 ml/(kgÁmin). The MRT and Vss were 9.58 6 0.10 h and 144 6 45 L/kg, respectively.
The mean BPA and BPA-G maternal Css were 19.36 6 7.06 nM (4.42 6 1.61 ng/ml) and 202 6 90 nM (82 6 36 ng/ CORBEL ET AL. MATERNAL-FETAL EXPOSURE TO BPA AND ITS METABOLITES ml), respectively (Table 3) , and became lower than the LOQ after the end of the fetal BPA infusion (Fig. 2A) . The mean BPA-S maternal Css was 18 nM in one ewe and lower than the LOQ in two ewes. The mean ratio of fetal to maternal BPA concentration at steady state was 6.17 6 2.45. The mean BPA-G:BPA ratios were higher in fetuses than in mothers (78 vs. 11). In amniotic fluid, BPA-G steady-state levels (1389 6 1075 nM [561 6 434 ng/ml]), while high and variable, remained lower than plasma levels (t-test, P , 0.05). After the BPA fetal infusion, the fractions of BPA, BPA-G, and BPA-S at steady state in fetal plasma were 1.22% 6 0.14%, 94.8% 6 0.4%, and 4.02% 6 0.32%, respectively. The overall mean free plasma BPA fraction measured during BPA infusions in three fetuses was 10.06% 6 0.40%, which means that for the mean total BPA concentration of 24.9 ng/ml (109 nM), the calculated internal exposure of the fetuses to free bioactive BPA was 2.50 ng/ml (11 nM).
After the BPA-G fetal infusion at a dose of 3.54 mg/ (kgÁday) (Fig. 2B) , the mean fetal BPA-G Css was 11 207 6 4711 nM (4528 6 1903 ng/ml), and it remained very high until 48 h after the end of the infusion, then decreased slowly and was significantly lower than steady-state values 21 h afterward (P , 0.05). In amniotic fluid collected from one fetus, high BPA-G levels were detected (162 nM [65.53 ng/ml] at steady state) and remained relatively constant (233 nM [94.13 ng/ml]) 5 days after the end of the infusion. After the BPA-G fetal infusion, no BPA was detected in fetal plasma, and taking into account the BPA LOQ of 4.4 nM, it can be estimated that less than 0.04% of BPA-G could have been converted back to BPA in the fetus.
Neither BPA nor its metabolites were detected in the maternal plasma after a fetal infusion of BPA-G.
Maternal-fetal exposure after maternal infusion. Figure 3 illustrates the time courses of concentrations of BPA and its metabolites in maternal and fetal plasma for one representative pregnant ewe during and after a 24-h maternal intravenous infusion of BPA and of BPA-G.
After a BPA maternal infusion at a dose of 2 mg/(kgÁday), the mean maternal plasma BPA Css was 192 6 46 nM (44 6 10 ng/ml) ( Fig. 3A and Table 3 ) and then decreased rapidly, with a t 1/2 of 0.76 6 0.66 h. The mean BPA plasma clearance was 55.9 6 13.9 ml/(kgÁmin) ( Table 1 ). The mean fetal BPA Css was 25.2 6 12.6 nM (5.76 6 2.88 ng/ml), resulting in a mean ratio of total aglycone BPA levels between the mother and fetus of 7.61 6 2.39. The calculated maternal and fetal BPA free concentrations were 2.73 and 0.58 ng/ml, respectively, resulting in a mean ratio of free BPA levels between the mother and fetus of 4.7. The BPA placental transfer from maternal to fetal compartment calculated using Equation 3 was 4.53 6 2.55% of the maternal dose.
The fetal plasma BPA-G and BPA-S levels were very high (6092 6 4659 and 221 6 135 nM, respectively), resulting in a mean ratio of BPA conjugates between the mother and fetus of 0.30 6 0.07 for BPA-G and 0.14 6 0.04 for BPA-S. The fetal plasma concentrations at steady state were close in two males and in six females: 20.92 6 5.91 versus 26.67 6 14.34 nM for BPA, 5108 6 2674 versus 6419 6 5333 nM for BPA-G, and 166 6 92 versus 240 6 148 nM for BPA-S. The mean BPAconjugates:BPA ratios were much higher in fetuses compared to mothers (251 vs. 9.4 for BPA-G and 8.75 vs. 0.15 for BPA-S; t-test, P , 0.001). They remained relatively constant after the end of the BPA infusion, decreased slowly, and were significantly lower than steady-state values 10 and 4 hours later (P , 0.05).
In amniotic fluid, BPA was not detected, but steady-state BPA-G levels, while high and variable (1450 6 1766 nM), remained lower than plasma levels (t-test, P , 0.05).
After the BPA maternal infusion, the fractions of BPA, BPA-G, and BPA-S at steady state were 10.14% 6 2.71%, 88.50% 6 2.52%, and 1.36% 6 0.23%, respectively, of total BPA in maternal plasma and 0.49% 6 0.25%, 95.42% 6 2.41%, and 4.09% 6 2.20%, respectively, of total BPA in fetal plasma.
After the BPA-G maternal infusion at a dose of 3.54 mg/ (kgÁday) (Fig. 3B) , the maternal plasma BPA-G concentrations decreased rapidly, with a t 1/2 of 3.59 h ( Table 2) . BPA was not detected in plasma of the ewe.
Neither BPA nor its metabolites were detected in the fetal plasma or in the amniotic fluid after a maternal infusion of BPA-G.
Placental Clearances
The total fetal clearance (515 ml/min), calculated using the two-compartment open TK model [19] , was relatively low compared with the total maternal clearance (2698 ml/min). However, when normalized to the respective body weight, the total fetal clearance (206 ml/[kgÁmin]) was fourfold higher than the total maternal clearance (46.7 ml/[kgÁmin]). These total maternal and fetal BPA clearances are in very close agreement with those resulting from the noncompartmental TK analysis. The transplacental clearance from fetus to mother (470 ml/min) was approximately sevenfold higher than that from mother to fetus (67 ml/min). Maternal nonplacental clearance (2631 ml/ min) accounted for 98% of the maternal total clearance, whereas fetal nonplacental clearance (44.3 ml/min) accounted for only 8.6% of the fetal total clearance.
DISCUSSION
Pregnancy represents a critical window of exposure for the fetus during which developmental processes are extremely sensitive to estrogenic interferences. BPA is one of the xenobiotics of major concern for fetal development. The degree of human exposure to BPA, particularly during pregnancy and fetal development, is not clear. This highlights the urgent need for a better understanding and characterization of the dynamics of maternal-fetal-placental exchanges of BPA based on data obtained in a model relevant for studying the interaction of the maternal-placental-fetal unit in humans.
The main result obtained in the present physiological model of pregnant ewe is that 4.5% of a BPA dose intravenously infused into pregnant ewes was transferred across the placenta to the fetus, where it was rapidly conjugated into BPA-G and BPA-S. These metabolites then remained trapped in the fetal compartment. In agreement with this result, approximately 4% of a radiolabeled BPA dose was recovered in the fetal compartment (whole litter, placenta and amniotic fluid) in CD-1 pregnant mice 24 h after BPA administration [20] . Considering the body weight ratio of 25 between the dam and its fetus, it can be estimated that the fetus was exposed to a similar external BPA dose as its mother (i.e., 2.08 mg/[kgÁday], for a maternal BPA dose of 2 mg/[kgÁday]).
The main objective of the present study was to determine if maternal exposure to BPA during the pregnancy led to a higher fetal BPA exposure during the critical window of development. From our ovine model, we have shown that the pregnancy modified neither the maternal internal exposure to total or free BPA and its metabolites, nor the TK parameters of BPA and BPA-G. Furthermore, the plasma unbound BPA fraction of 6% remained similar in nonpregnant and in pregnant ewes, whatever the pregnancy stage. This value is similar to the 
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unbound fraction of BPA in humans, which ranges from 5% to 8% [21] .
Our in vivo sheep model has the advantage of being an integrated physiological system to evaluate the BPA fetal exposure resulting from maternal exposure. We have demonstrated that maternal exposure to BPA did not lead to overexposure of the fetus to the unconjugated form of BPA: The total and free (unbound) bioactive BPA fetal plasma levels were approximately 7.6-and 4.7-fold lower, respectively, than the maternal ones. The difference between the two ratios could be explained at least in part by the twofold lower plasma albumin concentration in the late gestation fetus compared to ewes [22] . However, we cannot exclude that fetal albumin could have a lower affinity for BPA than maternal albumin. In contrast, the fetuses were three-and eightfold more exposed to glucurono-and sulfoconjugates, respectively, than their mothers after a BPA maternal exposure. The unbalanced sex ratio did not enable us to provide definitive assessments on potential sex differences in fetal BPA, BPA-G, and BPA-S internal exposure, but our data suggest that gender might not influence fetal BPA disposition. This internal exposure scheme characterized in the ovine conceptus is in agreement with a previous study using an ovine model to characterize neonatal exposure [23] , with some human biomonitoring data [1, 24, 25] , and with a recent study performed in rhesus monkeys [26] indicating that maternal plasma unconjugated BPA concentrations are greater than those in cord blood.
Indeed, after maternal BPA administration, the BPA internal exposure of mother and fetus reached approximately 40 and 6 ng/ml, respectively, which are values close to the highest previously reported for human maternal and fetal internal exposures [16, 27] . These concentrations corresponded to a maternal:fetal ratio of unconjugated BPA of approximately seven, a value close to the ratio between maternal blood and umbilical cord blood reported in some human biomonitoring studies [27] , indicating that the fetus was not more exposed to BPA than its mother. Different factors such as the BPA and BPA-G physicochemical properties, plasma protein binding, placental blood flows, efficiency of maternal and fetal drug elimination, and gestational age of the fetus have been postulated to affect the degree of placenta BPA and BPA-G transfer and thus fetal BPA exposure [28] . The computation of placental and nonplacental clearances has shown that the maternal nonplacental clearance appears to be the major determinant of maternal exposure. In contrast to the mother, the fetal-placental pathway, including BPA placental transfer from fetal to maternal compartment and BPA placental metabolism, is the major determinant of fetal exposure.
In the maternal compartment, 98% of the BPA infused into the mother was eliminated via maternal nonplacental routes. This result is consistent with a high maternal BPA plasma clearance, which was of the same order of magnitude as the hepatic blood flow (S.H. Collet, personal communication) and not influenced by the pregnancy status. The limited BPA maternal placental clearance is of the same order of magnitude as the calculated 4.5% rate of BPA maternal transfer into the fetus.
The high fetal-maternal and maternal-fetal placental permeability of lipid-soluble BPA could be explained by the physicochemical properties, which point toward a possibility of placental transfer of BPA by passive diffusion in both maternal-to-fetal and fetal-to-maternal directions. Nevertheless, considering the species differences in placental structure, with only three layers separating maternal and fetal blood in human hemochorial placenta and five to six layers in ovine syndesmochorial placenta, we can speculate that the BPA fetal placental transfer could be higher in humans than the 4% observed in our ovine model. To further investigate this placentation effect, a cannulated nonhuman primate model could be used to assess the relevance of the ovine model for evaluating BPA placental transfer.
The fetal-maternal placental clearance was sevenfold higher than the maternal-fetal one. Different reasons could explain this higher value of fetal placental clearance. First, the difference in the placental contribution to BPA maternal or fetal total clearance could be explained by the ratio between the placental blood flow and the total cardiac output, which is 60% in the fetus and only 5% in the mother [29] . Second, the maternal placental clearance could be underestimated by a fetal hepatic first-pass uptake of a portion of the BPA transferred to the fetus across the placenta, as demonstrated by Kumar [10] . Indeed, BPA infused into the mother reaches the fetal circulation via the umbilical vein, and in late gestation, 45% of the umbilical venous blood flow passes through the ovine fetal liver before reaching the fetal circulation [30] . In addition, BPA is a substrate of the P-glycoprotein efflux pump [31] , an efflux mechanism that plays a role in the protection of fetus against toxic xenobiotics [32] and that could reduce the maternal BPA placental transfer into the fetus.
In the fetus, the average placental clearance of BPA was approximately 94% of the umbilical blood flow estimated in sheep at this stage of pregnancy (200 ml/[kgÁmin] [30] ), suggesting a high rate of BPA placental transfer. Only 9% of the BPA infused into the fetus was eliminated via fetal nonplacental routes. The low weight-corrected BPA nonplacental clearance of 17.7 ml/(kgÁmin), corresponding to approximately 14% of the reported liver blood flow in lamb fetuses [30] , could be due to a limited activity of uridine 5 0 -diphospho-glucuronosyltransferase in fetal liver, as demonstrated in vitro in several species, including sheep [3] and humans [4, 33] . The high total fetal BPA clearance (206 ml/ [kgÁmin]) and the exposure pattern of BPA metabolites in the conceptus (ratio between unconjugated BPA and total BPA fetal plasma concentrations , 1.5%) indicates that the fetalplacental unit, at least toward the end of pregnancy, was able to detoxify BPA through phase II metabolism. Furthermore, our results suggest that the ovine fetal-placental unit presents a higher activity of sulfation in comparison with adults. In mammals, sulfotransferases are expressed early in the fetus, and in humans, sulfotransferase activities are detected in the fetus at levels equivalent to or higher than those in the adult [34] .
In our dynamic equilibrium conditions allowing quantification of the conjugation/deconjugation balance of BPA, no BPA was detected in either the maternal or the fetal compartment after BPA-G administration in the corresponding compartment, suggesting that conjugation is highly predominant compared to hydrolysis, even in the fetus with vulnerable drug-metabolizing systems. Even if BPA-S is a minor BPA metabolite compared to BPA-G, its conjugation/deconjugation balance could be different from that of BPA-G due to the known capacity of the placenta and other tissues to deconjugate sulfated steroids. This requires further investigation.
In the fetus, the production of BPA conjugates increases fetal exposure to these water-soluble metabolites, because they are less able to cross the placenta [35] [36] [37] and, once excreted in urine, are trapped in the amniotic fluid and can be swallowed and recirculated in the fetus. Thus, in our model, more than 180 lg/day of BPA-G in amniotic fluid could be swallowed daily by the late gestation ovine fetus [38] .
In conclusion, our in vivo integrated approach enabled us to identify the placental transfer of BPA and its metabolism in the fetal-placental compartment as the major determining factors of fetal exposure to BPA. At the late stage of pregnancy, the BPA CORBEL ET AL. dose received by the fetus following the administration to the mother is close to the initial dose given to its mother. The fetalplacental unit shows high and sustained internal exposure to BPA metabolites without evidence of reactivation and recirculation of native BPA. Nevertheless, this result raises the question of the potential local reactivation of the conjugates into native (biologically active) BPA within the fetal target tissues (gonad and brain).
The high placental permeability of lipid-soluble BPA suggests that the BPA placental transfer determined in sheep could be considered relevant for humans despite the interspecies difference in placental structure. However, placental and fetal BPA metabolic differences during pregnancy and between species will have to be investigated to establish the full relevance of animal models in evaluating the danger of fetal exposure to BPA in humans.
